Detailed information for compound 34404

Basic information

Technical information
  • TDR Targets ID: 34404
  • Name: 2-[[4-[(2,4-diaminopteridin-6-yl)methylamino] benzoyl]amino]-4-sulfobutanoic acid
  • MW: 476.466 | Formula: C18H20N8O6S
  • H donors: 6 H acceptors: 10 LogP: -1.21 Rotable bonds: 10
    Rule of 5 violations (Lipinski): 2
  • SMILES: OC(=O)C(NC(=O)c1ccc(cc1)NCc1cnc2c(n1)c(N)nc(n2)N)CCS(=O)(=O)O
  • InChi: 1S/C18H20N8O6S/c19-14-13-15(26-18(20)25-14)22-8-11(23-13)7-21-10-3-1-9(2-4-10)16(27)24-12(17(28)29)5-6-33(30,31)32/h1-4,8,12,21H,5-7H2,(H,24,27)(H,28,29)(H,30,31,32)(H4,19,20,22,25,26)
  • InChiKey: ZLLDSRTXPHYVLX-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 2-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]-4-sulfo-butanoic acid
  • 2-[[[4-[(2,4-diamino-6-pteridinyl)methylamino]phenyl]-oxomethyl]amino]-4-sulfobutanoic acid
  • 2-[[4-[[2,4-bis(azanyl)pteridin-6-yl]methylamino]phenyl]carbonylamino]-4-sulfo-butanoic acid
  • 2-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]-4-sulfo-butyric acid
  • 2-[[4-[(2,4-diaminopteridin-6-yl)methylamino]phenyl]carbonylamino]-4-sulfo-butanoic acid
  • 96193-19-0
  • 2-((4-(((2,4-Diaminopteridin-6-yl)methyl)amino)phenyl)carbonylamino)-4-sulfobutanoic acid
  • 2-[(4-{[(2,4-Diaminopteridin-6-yl)methyl]amino}phenyl)carbonylamino]-4-sulfobutanoic acid
  • AIDS-097018
  • AIDS097018

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Mycobacterium ulcerans proteasome PrcA 0.1788 0.455 1
Trypanosoma cruzi NADH-ubiquinone oxidoreductase, mitochondrial, putative 0.0782 0.1405 0.5
Loa Loa (eye worm) hypothetical protein 0.036 0.0087 0.0087
Echinococcus multilocularis NADH dehydrogenase (ubiquinone) flavoprotein 1 0.0782 0.1405 0.0589
Echinococcus multilocularis tyrosine protein phosphatase non receptor type 0.3532 1 1
Mycobacterium ulcerans NADH dehydrogenase I subunit F 0.0782 0.1405 0.2304
Mycobacterium tuberculosis Probable NADH dehydrogenase I (chain F) NuoF (NADH-ubiquinone oxidoreductase chain F) 0.0782 0.1405 0.2304
Trypanosoma brucei NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial 0.0782 0.1405 0.5
Leishmania major NADH-ubiquinone oxidoreductase, mitochondrial, putative 0.0782 0.1405 0.5
Trypanosoma cruzi NADH-ubiquinone oxidoreductase, mitochondrial, putative 0.0782 0.1405 0.5
Loa Loa (eye worm) NADH-ubiquinone oxidoreductase 51 kDa subunit 0.0782 0.1405 0.1405
Onchocerca volvulus NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial homolog 0.0419 0.0271 0.5
Trichomonas vaginalis NADH-ubiquinone oxidoreductase flavoprotein, putative 0.0782 0.1405 0.5
Echinococcus granulosus tyrosine protein phosphatase non receptor type 0.3532 1 1
Brugia malayi hypothetical protein 0.036 0.0087 0.0087
Echinococcus granulosus Receptor type tyrosine protein phosphatase O 0.1504 0.3661 0.3353
Mycobacterium leprae probable proteasome (alpha subunit) PrcA 0.1788 0.455 0.5
Mycobacterium tuberculosis Proteasome alpha subunit PrcA; assembles with beta subunit PrcB. 0.1788 0.455 1
Trypanosoma brucei NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial, putative 0.0782 0.1405 0.5
Loa Loa (eye worm) protein-tyrosine phosphatase 0.3532 1 1
Schistosoma mansoni NADH-ubiquinone oxidoreductase 0.0782 0.1405 0.0987
Echinococcus granulosus receptor type tyrosine protein phosphatase 0.061 0.0867 0.0423
Wolbachia endosymbiont of Brugia malayi NADH dehydrogenase I subunit F 0.0782 0.1405 1
Schistosoma mansoni protein tyrosine phosphatase non-receptor type nt1 0.3532 1 1
Brugia malayi NADH-ubiquinone oxidoreductase 51 kDa subunit, mitochondrial precursor 0.0782 0.1405 0.1405
Echinococcus granulosus NADH dehydrogenase ubiquinone flavoprotein 1 0.0782 0.1405 0.0987
Echinococcus granulosus receptor type tyrosine protein phosphatase 0.061 0.0867 0.0423
Trichomonas vaginalis NADH-ubiquinone oxidoreductase flavoprotein, putative 0.0782 0.1405 0.5

Activities

Activity type Activity value Assay description Source Reference
Activity (functional) = -8 % In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring 7-day weight change after intraperitoneal administration of compound at 1 mg/kg ChEMBL. 6546949
Activity (functional) = -8 % In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring 7-day weight change after intraperitoneal administration of compound at 2 mg/kg ChEMBL. 6546949
Activity (functional) = -8 % In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring 7-day weight change after intraperitoneal administration of compound at 1 mg/kg ChEMBL. 6546949
Activity (functional) = -8 % In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring 7-day weight change after intraperitoneal administration of compound at 2 mg/kg ChEMBL. 6546949
Activity (functional) = 88 % In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring percent increase in life span after intraperitoneal administration of compound at 0.5 mg/kg ChEMBL. 6546949
Activity (functional) = 88 % In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring percent increase in life span after intraperitoneal administration of compound at 0.5 mg/kg ChEMBL. 6546949
Activity (functional) = 100 % In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring percent increase in life span after intraperitoneal administration of compound at 1 mg/kg ChEMBL. 6546949
Activity (functional) = 100 % In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring percent increase in life span after intraperitoneal administration of compound at 1 mg/kg ChEMBL. 6546949
Activity (functional) = 138 % In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring percent increase in life span after intraperitoneal administration of compound at 2 mg/kg ChEMBL. 6546949
Activity (functional) = 138 % In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring percent increase in life span after intraperitoneal administration of compound at 2 mg/kg ChEMBL. 6546949
ID50 (functional) = 0.031 uM Compound was evaluated for its cytotoxicity against the L1210 murine leukemia cell culture ChEMBL. 6546949
ID50 (functional) = 0.031 uM Compound was evaluated for its cytotoxicity against the L1210 murine leukemia cell culture ChEMBL. 6546949
ID50 (functional) = 0.063 uM Compound was evaluated for its antitumor activity by the inhibition of L1210 murine leukemia dihydrofolate reductase ChEMBL. 6546949
ID50 (functional) = 0.063 uM Compound was evaluated for its antitumor activity by the inhibition of L1210 murine leukemia dihydrofolate reductase ChEMBL. 6546949
Inhibition (binding) = 77 % Inhibition of Folyl-polyglutamate synthase from mouse liver ChEMBL. 3385729
Inhibition (binding) = 77 % Inhibition of Folyl-polyglutamate synthase from mouse liver ChEMBL. 3385729
Ki (binding) = 45 uM Inhibition of Folyl-polyglutamate synthase from mouse liver ChEMBL. 3385729
Ki (binding) = 45 uM Inhibition of Folyl-polyglutamate synthase from mouse liver ChEMBL. 3385729
Ki (binding) = 59 uM Compound was evaluated for the binding affinity to mouse liver folyl polyglutamate synthetase. ChEMBL. 6546949
Ki (binding) = 59 uM Compound was evaluated for the binding affinity to mouse liver folyl polyglutamate synthetase. ChEMBL. 6546949
Survival days (functional) = 13 In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring number of survival days after intraperitoneal administration of compound at 0.5 mg/kg; at a range of 13-16 ChEMBL. 6546949
Survival days (functional) = 13 In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring number of survival days after intraperitoneal administration of compound at 1 mg/kg; at a range of 13-17 ChEMBL. 6546949
Survival days (functional) = 15 In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring T/C median after intraperitoneal administration of compound at 0.5 mg/kg; T/C median=15/8 ChEMBL. 6546949
Survival days (functional) = 16 In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring T/C median after intraperitoneal administration of compound at 1 mg/kg; T/C median=16/8 ChEMBL. 6546949
Survival days (functional) = 16 In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring number of survival days after intraperitoneal administration of compound at 2 mg/kg; at a range of 16-20 ChEMBL. 6546949
Survival days (functional) = 19 In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring T/C median after intraperitoneal administration of compound at 2 mg/kg; T/C median=19/8 ChEMBL. 6546949
Weight change (functional) = -1 % In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring 7-day weight change after intraperitoneal administration of compound at 0.5 mg/kg ChEMBL. 6546949
Weight change (functional) = -1 % In vivo antitumor activity was evaluated against L1210 leukemia implanted mice by measuring 7-day weight change after intraperitoneal administration of compound at 0.5 mg/kg ChEMBL. 6546949

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

2 literature references were collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.